FINWIRES · TerminalLIVE
FINWIRES

$STTK

3 stories mentioning STTK

Every FINWIRES story that references STTK, newest first.

Sectors

Sector Update: Healthcare Stocks Steady Pre-Bell Monday

Healthcare stocks were steady pre-bell Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up a slight 0.1%.Tango Therapeutics (TNGX) shares were up more than 45% after the company said initial results from its phase 1/2 trial of vopimetostat in combination with Revolution Medicines' inhibitor daraxonrasib showed a six-month progression-free survival rate of 90% in patients with pancreatic cancer.Eli Lilly (LLY) shares were up more than 2% after the company said additional phase 3 data showed that retatrutide achieved substantial weight loss with "meaningful" improvements in obesity-related conditions, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes.Shattuck Labs (STTK) said its phase 1 study of SL-325, a treatment for immune-related disease, showed good safety results and consistent drug performance in healthy volunteers. Shattuck Labs stock was up more than 14% premarket.

$IBB$LLY$STTK$TNGX$XLV
Research

Citigroup Upgrades Shattuck Labs to Buy From Neutral, Price Target is $7

Shattuck Labs (STTK) has an average rating of buy and mean price target of $12.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$STTK
Research

Cantor Fitzgerald Initiates Coverage on Shattuck Labs With Overweight Rating

Shattuck Labs (STTK) has an average rating of Buy and mean price target of $12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$STTK